It is possible that large airways (cartilaginous bronchi) play a role in flow limitation either by lumen narrowing due to mucosal cedema, mucous gland hyperplasia, and smooth muscle hypertrophy, or by expiratory atrophic collapse.
During the past years, great emphasis has been placed on a major increased flow resistance in the small conducting airways less than 2 mm in diameter (Hogg et al. 1968 ).
Four types of lesion have been described in terms of morphometric (Bignon et al. 1968 , Depierre et al. 1972 ) and fine structural data:
(1) Narrowing of nonrespiratory bronchioles presumably related to an inflammatory process. This change has been well demonstrated by microscopic measurements and by bronchial resin casts, including stenotic segments and diffuse narrowing at the level of nonrespiratory bronchioles less than 1 mm diameter.
(2) Loss of peripheral airways has been demonstrated, but only in emphysematous lungs (Depierre et al. 1972 , Matsuba & Thurlbeck 1972 . (3) Mucous plugging occurs but is difficult to assess in postmortem lungs fixed by airways infusion of formalin (Matsuba & Thurlbeck 1973) . (4) Some fine structural changes of the bronchiolar epithelium have been shown in lungs obtained at surgery for lung carcinoma or at autopsy from elderly smoking patients: by comparison to nonsmokers, we found a lower number of clara cells, replaced by flat microvillous and short ciliated cells and by some mucus-secreting cells with a microvillous surface. There were abnormal dense inclusions within the bronchiolar epithelium, possibly related to tobacco materials. These changes might be a cause of obstruction by compromising the permeability (mucous plugging) and the stability (loss of surface active material) of small airways (Macklem et al. 1970 , Ebert & Terracio 1975 Bignon, in answer to Dr J E Cotes, said that the lungs were inflated at a pressure of between 25 and
cmH20O
Dr G Cumming said that stenosis seen on a cast was often due to defective filling but it could be anatomical.
The clinical and physiological features during life could then mimic those of emphysema. Commenting on the relation between structure and function Dr Cumming said that in centrilobular emphysema involving all the respiratory bronchioles the proportion of affected lung tissue would be about 25 %, but the patient might be grossly disabled. With panacinar emphysema, it was very easy to get 60 % or 70 % of the lung parenchyma involved, but the patient might be only moderately disabled. Thus it was necessary to define the type of emphysema, but this was difficult because emphysema rarely occurred in a pure form. 
Dr P Davies and Dr A C Allison

Biochemical Markers of Lung Disease
The endogenous factors which damage lung tissue and the mechanisms by which they are released are now becoming apparent. When toxic agents are inhaled into the lungs they provoke inflammatory reactions which can be of an immune or nonimmune nature. Toxic particles such as silica or asbestos interact directly with phagocytic cells while protein antigens stimulate T and B lymphocytes to produce mediators of humoral and cell-mediated immunity respectively. These lymphocyte-derived factors interact with macrophages and polymorphonuclear leukocytes, causing the release of mediators of tissue damage. Both polymorphonuclear leukocytes and macrophages contain a wide range of tissuedegrading hydrolytic enzymes which are active at acid or neutral pH. These include proteinases such as elastase, collagenase and cathepsin D which can damage various constituents of bronchial and alveolar tissue and phospholipases which can attack lung surfactant. By the use of in vitro cell cultures and sensitive biochemical techniques we have been able to demonstrate that some of these hydrolytic enzymes can be released from macrophages exposed to several stimuli known to provoke inflammatory changes in the lung.
Chrysotile asbestos induces the selective release of large amounts of acid hydrolases from viable macrophages over long periods of time. This phenomenon is not observed with silica, which is cytotoxic to cultures of macrophages.
Products of stimulated B or T lymphocytes also induce the release from macrophages of hydrolytic enzymes active at both acid and neutral pH.
Immune complexes formed at equivalence induce the release of acid hydrolases while the products of stimulated T lymphocytes release both acid hydrolases and collagenase from macrophages.
It is clear that proteinases released from phagocytic cells have a great potential for damaging lung tissue; this is confirmed by the particular. susceptibility of individuals with decreased a-ltrypsin inhibitor capacity to chronic obstructive pulmonary disease. Since a-1-trypsin inhibitor inhibits serine proteinases such as elastase and a-2macroglobulin inhibits all classes of proteinases, these two substances play an important role in limiting tissue damage caused by proteinases.
Biochemical measurements of enzyme release from cultures of phagocytic cells have provided insight into the mechanisms by which lung damage can occur. They should also be useful as a predictive indicator of the potential toxicity of new materials such as glass fibres which are coming into industrial use.
DISCUSSION
Dr J C Gilson said that dose-response relationships obtained using tissue culture were difficult to interpret because the amount of particulate material in the different cells probably varied considerably.
Dr Davies, in reply to Dr J Bignon, said that in the context of chronic inflammation, polymorphs were probably not important. The macrophages were more long-lived and released lysosomal enzymes in response to immune complexes and other inflammatory stimuli.
Substances which were able to induce chronic inflammation in vivo also caused enzyme release in vitro.
Dr D C S Hutchison said that in a-l-antitrypsin deficiency there was a clear relationship to emphysema; but what of the other cases? He doubted if the immune complexes were produced in emphysema where the predominant lesion was not inflammation or fibrosis but the breakdown of elastic tissue. Most of such subjects were smokers. They had more macrophages in samples taken by bronchial lavage than did nonsmokers and the macrophages contained larger and more numerous lysosomes. The macrophages, on account of their location in the airways, were well placed to cause centrilobular emphysema, but the mechanism whereby the enzymes were released was not known. Dr Davies suggested that the release might be due to the accumulation within the macrophages of components of cigarette smoke, but he had no direct evidence. Dr J E Cotes asked if the concentration in plasma of either the released lysosomal enzymes or their inhibitors were high enough for them to be detectable by biochemical analysis. Dr Davies doubted if it would be possible to detect the enzymes themselves, though this was the case in certain metastatic diseases. In some inflammatory conditions there was elevation of the a-l-trypsin inhibitor, but the a-2-macroglobulin remained remarkably constant.
Dr D C S Hutchison (King's College Hospital, London SE5)
Homozygous and Heterozygous Alpha-1-antitrypsin Deficiency: Prevalence in Pulmonary Emphysema Alpha-1-antitrypsin (a-i-AT) exists in a number of inherited biochemical variants known collectively as the Pi system. Homozygotes of the common phenotype (MM) form 86 % of the normal population of the UK (Cook 1974 , Cole et al. 1974 , heterozygotes of type MZ, 3 % and of type MS, 9%. Homozygotes of type ZZ occur with a frequency of I in 3500 in the UK (Cook 1974) ; there are considerable variations between ethnic groups in the prevalence of these phenotypes (Kellerman & Walter 1970) .
Subjects of type ZZ have severe a-l-AT deficiency and a strong tendency to develop emphysema at an early age (Eriksson 1965) .. Variations in the quoted prevalence of type ZZ in emphysema reflect differences in diagnostic criteria (Kueppers et al. 1964 , Kueppers et al. 1969 The question whether heterozygotes of types MZ or MS have a predisposition towards lung disease has been approached in two main ways:
(1) Patients with emphysema or chronic airflow obstruction may be selected and their serum a-l-AT concentrations or Pi phenotypes compared with healthy controls. In three studies of similar design (Talamo et al. 1968 , Jones & Thomas 1971 , Hutchison et al. 1971 ) the mean a-I-AT concentration among patients with radiological evidence of emphysema was actually greater than in the controls, and no difference was found in the incidence of types MZ and MS (Cook & Hutchison 1975, unpublished) .
Different results have been obtained in studies (Kueppers & Donhardt 1974 , Lieberman et al. 1969 where selection of patients with chronic airflow obstruction has been based on lung function tests. From these it may be concluded that MZ subjects have an increased tendency to develop lung disease, whereas those of type MS do not.
(2) Subjects with a-l-AT concentration in the intermediate heterozygote range (or of MS or MZ phenotype) may be selected from a healthy population or from relatives of a ZZ propositus; clinical and radiological data, and lung function tests, are then compared with those of type MM.
Thus in two studies of working populations the incidence of symptoms in heterozygotes of types MZ and MS was no greater than in type MM and there was no difference in FEV1 between the two groups (Webb et al. 1973 , Cole et al. 1974 ).
